Back

HARBOR-AF: a multicentre, open-label, dose escalation study of the efficacy, safety, and tolerability of budiodarone for the treatment of subjects with paroxysmal atrial fibrillation

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiac rhythm disorders: devices, drugs, and outcomes Antiarrhythmic Drug Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Christian David Flynn

XYRA, LLC, San Francisco Bay (United States of America)

5 More presentations in this session

Presentation thumbnail
Nearly nine year follow-up data on a leadless pacing system real life experience in comparison to data of the prospective trial
Doctor S. Winter (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Omega-3 Fatty Acids reduce rate and QT-interval, but increase electrical instability in cardiomyocytes
Doctor C. Balbi (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Guidelines and heartlines: evaluating procainamide use at a large academic medical center
Doctor T. Ahuja (New York, US)
Abstract Slides Video
Presentation thumbnail
The advantages of using transtelephonic ECG monitoring device in outpatients with paroxysmal form of atrial fibrillation
Mrs M. Hamidzoda (Dushanbe, TJ)
Abstract Slides Video
Presentation thumbnail
Trends in arrhythmia-related mortality among adults with hyperthyroidism in the U.S. from 1999 to 2020: A CDC WONDER analysis
Miss O. Dairo (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac rhythm disorders: devices, drugs, and outcomes

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Late-Breaking Science: paroxysmal atrial fibrillation ablation
thumbnail
Congress Presentation
ALONE-AF: Discontinuing long-Term oral anticoagulation after successful atrial fibrillation ablation
thumbnail
Congress Presentation
ABC-AF study - a randomised controlled study of personalised treatment to reduce stroke or death in atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources